MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VYGR had $3,925K increase in cash & cash equivalents over the period. -$31,255K in free cash flow.

Cash Flow Overview

Change in Cash
$3,925K
Free Cash flow
-$31,255K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-27,892 -64,403
Stock-based compensation expense
3,460 7,806
Depreciation
932 2,079
Amortization of premiums and discounts on marketable securities
654 1,789
Loss on disposal of fixed assets
0 -79
Non-cash lease expense
1,233 2,376
Accounts receivable
1,512 170
Related party collaboration receivable
0 175
Prepaid expenses and other current assets
-3,153 1,826
Accounts payable
312 -2,192
Accrued expenses
2,831 -2,146
Operating lease liabilities
-1,836 -3,522
Deferred revenue
-11,075 -7,273
Net cash used in operating activities
-31,048 -71,156
Purchases of property and equipment
207 1,763
Purchases of marketable securities
6,636 114,790
Proceeds from sales and maturities of marketable securities
41,731 159,687
Net cash provided by (used in) investing activities
34,888 43,134
Proceeds from the exercise of stock options
85 161
Proceeds from the purchase of common stock under espp
0 434
Net cash provided by financing activities
85 595
Net (decrease) increase in cash, cash equivalents, and restricted cash
3,925 -27,427
Cash and cash equivalents at beginning of period
74,241 -
Cash and cash equivalents at end of period
50,739 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics, Inc. (VYGR)